Weber, Christopher J.Carrillo, Maria C.Jagust, WilliamJack, Clifford R., Jr.Shaw, Leslie M.Trojanowski, John Q.Saykin, Andrew J.Beckett, Laurel A.Sur, CyrilleRao, Naren P.Mendez, Patricio ChremBlack, Sandra E.Li, KunchengIwatsubo, TakeshiChang, Chiung-ChihSosa, Ana LuisaRowe, Christopher C.Perrin, Richard J.Morris, John C.Healan, Amanda M.B.Hall, Stephen E.Weiner, Michael W.2023-04-262023-04-262021-12-31Weber CJ, Carrillo MC, Jagust W, et al. The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives. Alzheimers Dement (N Y). 2021;7(1):e12226. Published 2021 Dec 31. doi:10.1002/trc2.12226https://hdl.handle.net/1805/32609The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW‐ADNI) is a collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's disease treatment trials. It is a public‐private partnership that spans North America, Argentina, Australia, Canada, China, Japan, Korea, Mexico, and Taiwan. In 2004, ADNI researchers began a naturalistic, longitudinal study that continues today around the globe. Through several successive phases (ADNI‐1, ADNI‐GO, ADNI‐2, and ADNI‐3), the study has fueled amyloid and tau phenotyping and refined neuroimaging methodologies. WW‐ADNI researchers have successfully standardized analyses and openly share data without embargo, providing a rich data set for other investigators. On August 26, 2020, the Alzheimer's Association convened WW‐ADNI researchers who shared updates from ADNI‐3 and their vision for ADNI‐4.en-USAttribution-NonCommercial-NoDerivatives 4.0 InternationalAlzheimer's diseaseAmyloidBiomarkersCerebrospinal fluidCognitive impairmentMRINeuroimagingPETTauArticle